Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 24; no. 4; p. 1275
• Main Authors: Zhao, Ya-Ling, Liu, Gui-Min, Zhang, Li-Jun, Liang, Wen-Tong, Cheng, Zhi-Yong
• Format: Journal Article
• Language: Chinese
• Published: China 01.08.2016
• Subjects: Hematologic Neoplasms; Humans; Janus Kinase 2; Mutation; Signal Transduction; STAT Transcription Factors
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2016.04.059

Jauns kinase (JAK)/transducer and activator of transcription（STAT） pathway is a classical approach to study the rapid changes of the gene expression in specific target cells by a variety of extracellular signals. The JAK and STAT transfer cytokine receptor signaling plays a unique role in multiple cellular and molecular biological changes.The abnormal signal of JAK/STAT pathway will lead to the hematopoietic abnormalities.Studies had shown that the abnormal activation of JAK2/STAT signaling pathway are in many kinds of malignant hematological diseases, such as in acute lymphoblastic/myeloid leukemia, chronic myeloid leukemia, lymphoma, myelodysplastic syndromes, myeloprofilerative neoplasm, especially in the patients of myeloproliferative neoplasm(MPN) with JAK gene mutation(JAK2V617F), this mutation has an important value for MPN diagnosis. At present, the effect of the specific inhibitors of JAK2 has showed good perspective, which had been applied to clinic treatment and achieved remarkable curative effect.